Lupin Ltd (LUPIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Lupin Ltd (Lupin) focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-TB and cephalosporins. It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation. Lupin develops value-added generic pharmaceuticals based on its platform technologies. The company along with its subsidiaries has manufacturing facilities in India, the US, Japan, Mexico and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.

Lupin Ltd (LUPIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 6
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Lupin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Lupin Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lupin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Lupin Ltd, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Kyowa Pharma to Acquire 21 Products from Shionogi 15
Lupin to Acquire Product Portfolio from Temmler Pharma 16
Lupin Plans To Acquire US Branded Drugs 17
Venture Financing 18
Symbiomix Therapeutics Raises USD6 Million in Venture Financing 18
Symbiomix Therapeutics Raises USD41 Million in Series A Financing 19
Symbiomix Therapeutics Raises USD20 Million in Venture Financing 20
Private Equity 21
Bayer May Sell Dermatology Business 21
Partnerships 22
Lupin and Mylan Enter into Partnership Agreement 22
Lupin and Nichi-Iko Enter into Partnership Agreement 23
Lupin, CSIR-National Chemical Laboratory and DST Enter into Research Agreement 24
Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 25
Boehringer Ingelheim Expands Co-Marketing Agreement with Lupin 26
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 27
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 28
Lupin Enters into Development Agreement with Celon for Generic Advair Diskus 29
Lupin Enters into Co-Development Agreement with Merck Serono 30
Lupin Enters into Distribution Agreement with Salix Pharma 31
Lupin Enters into Distribution Agreement with LG Life Sciences for Insulin Analogue Glargine 32
Lupin Enters Into Joint Venture Agreement With Yoshindo To Form YL Biologics 33
Gavis Pharma Partners with Modavar Pharma 34
Lupin Enters Into Co-Promotion Agreement With Onset Dermatologics For Locoid Lotion 35
Licensing Agreements 36
Lupin Enters into Licensing Agreement with Eli Lilly and Company 36
Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 37
Lupin Enters into Licensing Agreement with Medicines Patent Pool 38
Romark Labs Enters Into Licensing Agreement With Lupin For Alinia 39
Merck Enters Into Licensing Agreement With Lupin 40
Equity Offering 41
Lupin Plans to Raise USD1.2 Billion in Public Offering of Equity Securities 41
Asset Transactions 42
G&W Labs to Acquire Two Generic Drugs of Gavis Pharma from Lupin 42
Lupin to Acquire Product Portfolio from Temmler Pharma 43
Acquisition 44
Lupin Pharma Acquires Symbiomix Therapeutics 44
Lupin Acquires GAVIS Pharma for USD880 Million 45
Lupin Acquires Biocom 46
Lupin Acquires Medquimica 47
Lupin to Acquire Remaining 40% Stake in Pharma Dynamics 48
Lupin Acquires Labs Grin, Ophthalmology Therapies Provider 49
Lupin Plans to Acquire Generics Manufacturing Companies In Europe for up to USD1 Billion 50
Lupin Acquires Nanomi 51
Gavis Pharma Revises Open Offer Price To Acquire Additional 26% Stake In Wintac For US$5 Million 52
Aenova Completes Acquisition Of Temmler Pharma, Contract Manufacturing Company 53
Lupin Ltd - Key Competitors 54
Lupin Ltd - Key Employees 55
Lupin Ltd - Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Joint Venture 60
Recent Developments 61
Strategy And Business Planning 61
May 09, 2017: Lupin Announces Opening of its new 100,000 square foot expansion at its Somerset, NJ Manufacturing Site 61
Financial Announcements 62
Oct 31, 2018: Lupin quarter II, FY2019 - results 62
Aug 08, 2018: LUPIN: Quarter I, FY2019 -results 64
May 15, 2018: Lupin announces fiscal year 2018 Results, Board recommends dividend of 250% 66
Feb 06, 2018: Lupin Quarter III, FY2018-Results 68
Oct 30, 2017: Lupin Quarter II, FY2018 - Results 70
May 24, 2017: Lupin Announces Quarter IV and Annual Results, FY2017 72
Feb 09, 2017: Lupin Quarter III Results, FY2017 74
Corporate Communications 76
Sep 18, 2018: Lupin appoints Alok Sonig as CEO US Generics and Global Head Generics R&D & Biosimilars 76
May 31, 2018: Lupin appoints Nicholas Hart as President Specialty for US Business 77
Sep 18, 2017: Lupin appoints Jim Loerop as Chief Corporate Development Officer 78
Legal and Regulatory 79
Oct 19, 2018: Lupins Pithampur unit-3 (Indore) inspected by US FDA 79
Sep 14, 2018: Lupins Nagpur facility inspection by US FDA concluded with no observation 80
Sep 04, 2018: Lupins Tarapur API Manufacturing Facility Inspected by US FDA 81
Aug 24, 2018: Lupins Nagpur facility receives Establishment Inspection Report from US FDA 82
Jul 30, 2018: Lupins mandideep facility gets approval from EDQM 83
Jul 16, 2018: Lupins Goa facility gets approval from UK MHRA 84
May 14, 2018: Lupins Nagpur facility US FDA inspection concluded with no observations 85
Apr 06, 2018: Lupins Pithampur Unit 1 facility receives Establishment Investigation report (EIR) from US FDA 86
Apr 03, 2018: Lupins Goa facility completes successful UK MHRA inspection 87
Apr 02, 2018: Lupins Pithampur Unit cleared by Health Canada 88
Aug 21, 2017: Lupin receives EIR from US FDA for Aurangabad, April 2017 Inspection 89
Jul 31, 2017: Lupins Aurangabad facility inspection concluded by US FDA 90
Jul 28, 2017: Lupins Pithampur facility inspection concluded by US FDA without any observations 91
Government and Public Interest 92
Jun 29, 2018: Lupin announces tie-up with European Association of Urology (EAU) 92
Product News 93
05/27/2017: Lupin Pharmaceuticals Announces a Nationwide Recall of Mibelas 24 Fe (Norethindrone Acetate and Ethinyl Estradiol 1mg/0.02mg Chewable Tablets and Ferrous Fumarate 75mg) Tablets 93
May 10, 2018: Lupin launches Corcal Bone and Beauty supplement 94
03/16/2017: Lupin launches Generic Minastrin 24 Fe chewable tablets in the US 95
Other Significant Developments 96
Jul 21, 2017: Lupins Goa facility inspection concluded by US FDA without any observations 96
Appendix 97
Methodology 97
About GlobalData 97
Contact Us 97
Disclaimer 97

List Of Tables


Lupin Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Lupin Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Lupin Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Lupin Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Lupin Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Kyowa Pharma to Acquire 21 Products from Shionogi 15
Lupin to Acquire Product Portfolio from Temmler Pharma 16
Lupin Plans To Acquire US Branded Drugs 17
Symbiomix Therapeutics Raises USD6 Million in Venture Financing 18
Symbiomix Therapeutics Raises USD41 Million in Series A Financing 19
Symbiomix Therapeutics Raises USD20 Million in Venture Financing 20
Bayer May Sell Dermatology Business 21
Lupin and Mylan Enter into Partnership Agreement 22
Lupin and Nichi-Iko Enter into Partnership Agreement 23
Lupin, CSIR-National Chemical Laboratory and DST Enter into Research Agreement 24
Astellas Pharma Enters into Distribution Agreement with Kyowa Pharma 25
Boehringer Ingelheim Expands Co-Marketing Agreement with Lupin 26
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 27
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 28
Lupin Enters into Development Agreement with Celon for Generic Advair Diskus 29
Lupin Enters into Co-Development Agreement with Merck Serono 30
Lupin Enters into Distribution Agreement with Salix Pharma 31
Lupin Enters into Distribution Agreement with LG Life Sciences for Insulin Analogue Glargine 32
Lupin Enters Into Joint Venture Agreement With Yoshindo To Form YL Biologics 33
Gavis Pharma Partners with Modavar Pharma 34
Lupin Enters Into Co-Promotion Agreement With Onset Dermatologics For Locoid Lotion 35
Lupin Enters into Licensing Agreement with Eli Lilly and Company 36
Lupin Pharma Enters into Licensing Agreement with MonoSol Rx 37
Lupin Enters into Licensing Agreement with Medicines Patent Pool 38
Romark Labs Enters Into Licensing Agreement With Lupin For Alinia 39
Merck Enters Into Licensing Agreement With Lupin 40
Lupin Plans to Raise USD1.2 Billion in Public Offering of Equity Securities 41
G&W Labs to Acquire Two Generic Drugs of Gavis Pharma from Lupin 42
Lupin to Acquire Product Portfolio from Temmler Pharma 43
Lupin Pharma Acquires Symbiomix Therapeutics 44
Lupin Acquires GAVIS Pharma for USD880 Million 45
Lupin Acquires Biocom 46
Lupin Acquires Medquimica 47
Lupin to Acquire Remaining 40% Stake in Pharma Dynamics 48
Lupin Acquires Labs Grin, Ophthalmology Therapies Provider 49
Lupin Plans to Acquire Generics Manufacturing Companies In Europe for up to USD1 Billion 50
Lupin Acquires Nanomi 51
Gavis Pharma Revises Open Offer Price To Acquire Additional 26% Stake In Wintac For US$5 Million 52
Aenova Completes Acquisition Of Temmler Pharma, Contract Manufacturing Company 53
Lupin Ltd, Key Competitors 54
Lupin Ltd, Key Employees 55
Lupin Ltd, Other Locations 57
Lupin Ltd, Subsidiaries 57
Lupin Ltd, Joint Venture 60

List Of Figures


Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Lupin Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Lupin Ltd (LUPIN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Lupin Ltd (Lupin) focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular,

USD 250 View Report

Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review

Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by it

USD 125 View Report

Lupin Ltd (LUPIN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Lupin Ltd (Lupin) focuses on the development and manufacture of generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular,

USD 250 View Report

Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review

Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by it

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available